{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:39:55Z","timestamp":1793911195663,"version":"4.8.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003756","name":"Biomedicum Helsinki-s\u00e4\u00e4ti\u00f6","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003756","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010135","name":"Finska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007797","name":"Helsingin Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in general, with a particular focus on adenoviruses. These serve as a model to elucidate how versatile viruses are, and how they can be used to complement other cancer therapies to gain optimal patient benefits. Historical reports from over a hundred years suggest treatment efficacy and safety with adenovirus and other oncolytic viruses. This is confirmed in more contemporary patient series and multiple clinical trials. Yet, while the first viruses have already been granted approval from several regulatory authorities, room for improvement remains.<\/jats:p><jats:p>As good safety and tolerability have been seen, the oncolytic virus field has now moved on to increase efficacy in a wide array of approaches. Adding different immunomodulatory transgenes to the viruses is one strategy gaining momentum. Immunostimulatory molecules can thus be produced at the tumor with reduced systemic side effects. On the other hand, preclinical work suggests additive or synergistic effects with conventional treatments such as radiotherapy and chemotherapy. In addition, the newly introduced checkpoint inhibitors and other immunomodulatory drugs could make perfect companions to oncolytic viruses. Especially tumors that seem not to be recognized by the immune system can be made immunogenic by oncolytic viruses. Logically, the combination with checkpoint inhibitors is being evaluated in ongoing trials. Another promising avenue is modulating the tumor microenvironment with oncolytic viruses to allow T cell therapies to work in solid tumors.<\/jats:p><jats:p>Oncolytic viruses could be the next remarkable wave in cancer immunotherapy.<\/jats:p>","DOI":"10.1186\/s13045-020-00922-1","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T13:03:52Z","timestamp":1593435832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":325,"title":["Oncolytic viruses for cancer immunotherapy"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-2391","authenticated-orcid":false,"given":"Otto","family":"Hemminki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Manuel","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"issue":"13","key":"922_CR1","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1158\/0008-5472.CAN-09-1750","volume":"69","author":"SM Lippman","year":"2009","unstructured":"Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100\u2009years. Cancer Res. 2009;69(13):5269\u201384.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"922_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41430-018-0310-z","volume":"72","author":"G Segovia-Siapco","year":"2019","unstructured":"Segovia-Siapco G, Sabate J. Health and sustainability outcomes of vegetarian dietary patterns: a revisit of the EPIC-Oxford and the Adventist Health Study-2 cohorts. Eur J Clin Nutr. 2019;72(Suppl 1):60\u201370.","journal-title":"Eur J Clin Nutr"},{"issue":"6","key":"922_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"922_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2174\/1568009617666170502152352","volume":"18","author":"V Cerullo","year":"2018","unstructured":"Cerullo V, Capasso C, Vaha-Koskela M, Hemminki O, Hemminki A. Cancer-targeted oncolytic adenoviruses for modulation of the immune system. Curr Cancer Drug Targets. 2018;18(2):124\u201338.","journal-title":"Curr Cancer Drug Targets"},{"key":"922_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.omto.2018.04.003","volume":"9","author":"O Hemminki","year":"2018","unstructured":"Hemminki O, Oksanen M, Taipale K, Liikanen I, Koski A, Joensuu T, et al. Oncograms visualize factors influencing long-term survival of cancer patients treated with adenoviral oncolytic immunotherapy. Mol Ther Oncolytics. 2018;9:41\u201350.","journal-title":"Mol Ther Oncolytics"},{"issue":"16","key":"922_CR6","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jama.2010.491","volume":"303","author":"A Gratwohl","year":"2010","unstructured":"Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617\u201324.","journal-title":"JAMA."},{"issue":"1","key":"922_CR7","doi-asserted-by":"publisher","first-page":"10880","DOI":"10.1038\/s41598-018-28819-7","volume":"8","author":"L Zhang","year":"2018","unstructured":"Zhang L, Yu H, Hemminki O, Forsti A, Sundquist K, Hemminki K. Familial associations in testicular cancer with other cancers. Sci Rep. 2018;8(1):10880.","journal-title":"Sci Rep"},{"issue":"3","key":"922_CR8","doi-asserted-by":"publisher","first-page":"e0214410","DOI":"10.1371\/journal.pone.0214410","volume":"14","author":"L Zhang","year":"2019","unstructured":"Zhang L, Hemminki O, Chen T, Yu H, Zheng G, Chattopadhyay S, et al. Second cancers and causes of death in patients with testicular cancer in Sweden. PLoS One. 2019;14(3):e0214410.","journal-title":"PLoS One"},{"issue":"4","key":"922_CR9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48(4):812\u201330 e14.","journal-title":"Immunity."},{"issue":"8","key":"922_CR10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.15252\/emmm.201707567","volume":"9","author":"JD Freedman","year":"2017","unstructured":"Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol Med. 2017;9(8):1067\u201387.","journal-title":"EMBO Mol Med"},{"issue":"Suppl","key":"922_CR11","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","volume":"35","author":"DS Vinay","year":"2015","unstructured":"Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35(Suppl):S185\u2013S98.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"922_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell."},{"key":"922_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-med-112311-083918","volume":"64","author":"G Lizee","year":"2013","unstructured":"Lizee G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annu Rev Med. 2013;64:71\u201390.","journal-title":"Annu Rev Med"},{"issue":"1","key":"922_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/0976-9668.82318","volume":"2","author":"T Jessy","year":"2011","unstructured":"Jessy T. Immunity over inability: The spontaneous regression of cancer. J Nat Sci Biol Med. 2011;2(1):43\u20139.","journal-title":"J Nat Sci Biol Med"},{"issue":"4","key":"922_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/CAD.0000000000000337","volume":"27","author":"P Kucerova","year":"2016","unstructured":"Kucerova P, Cervinkova M. Spontaneous regression of tumour and the role of microbial infection\u2013possibilities for cancer treatment. Anti-Cancer Drugs. 2016;27(4):269\u201377.","journal-title":"Anti-Cancer Drugs"},{"key":"922_CR16","doi-asserted-by":"crossref","unstructured":"Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991;(262):3\u201311.","DOI":"10.1097\/00003086-199101000-00002"},{"issue":"4","key":"922_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.mt.6300108","volume":"15","author":"E Kelly","year":"2007","unstructured":"Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651\u20139.","journal-title":"Mol Ther"},{"issue":"9","key":"922_CR18","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/v2091844","volume":"2","author":"K Toth","year":"2010","unstructured":"Toth K, Wold WS. Increasing the efficacy of oncolytic adenovirus vectors. Viruses. 2010;2(9):1844\u201366.","journal-title":"Viruses."},{"issue":"10","key":"922_CR19","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/jama.1955.02960270006002","volume":"159","author":"RJ Huebner","year":"1955","unstructured":"Huebner RJ, Bell JA, Rowe WP, Ward TG, Suskind RG, Hartley JW, et al. Studies of adenoidal-pharyngeal-conjunctival vaccines in volunteers. J Am Med Assoc. 1955;159(10):986\u20139.","journal-title":"J Am Med Assoc"},{"issue":"6","key":"922_CR20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/1097-0142(195611\/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7","volume":"9","author":"RJ Huebner","year":"1956","unstructured":"Huebner RJ, Rowe WP, Schatten WE, Smith RR, Thomas LB. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9(6):1211\u20138.","journal-title":"Cancer."},{"issue":"3","key":"922_CR21","first-page":"217","volume":"19","author":"T Zielinski","year":"1969","unstructured":"Zielinski T, Jordan E. Remote results of clinical observation of the oncolytic action of adenoviruses on cervix cancer. Nowotwory. 1969;19(3):217\u201321.","journal-title":"Nowotwory."},{"key":"922_CR22","first-page":"49","volume":"10","author":"J Georgiades","year":"1959","unstructured":"Georgiades J, Zielinski T, Cicholska A, Jordan E. Research on the oncolytic effect of APC viruses in cancer of the cervix uteri; preliminary report. Biuletyn Instytutu Medycyny Morskiej w Gdansku. 1959;10:49\u201357.","journal-title":"Biuletyn Instytutu Medycyny Morskiej w Gdansku"},{"issue":"5286","key":"922_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"JR Bischoff","year":"1996","unstructured":"Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274(5286):373\u20136.","journal-title":"Science."},{"issue":"8","key":"922_CR24","first-page":"1502","volume":"57","author":"S Andreansky","year":"1997","unstructured":"Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997;57(8):1502\u20139.","journal-title":"Cancer Res"},{"issue":"2","key":"922_CR25","doi-asserted-by":"publisher","first-page":"e1074377","DOI":"10.1080\/2162402X.2015.1074377","volume":"5","author":"O Hemminki","year":"2016","unstructured":"Hemminki O, Hemminki A. A century of oncolysis evolves into oncolytic immunotherapy. Oncoimmunology. 2016;5(2):e1074377.","journal-title":"Oncoimmunology."},{"key":"922_CR26","first-page":"1483406","volume":"2019","author":"X Sun","year":"2019","unstructured":"Sun X, Gan L, Na A, Ge L, Chen B, Liu J. Combination with stereotactic body radiotherapy offers a promising strategy to overcome resistance to immunotherapy in advanced renal cell cancer. J Oncol. 2019;2019:1483406.","journal-title":"J Oncol"},{"key":"922_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","volume":"419","author":"J Wu","year":"2018","unstructured":"Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett. 2018;419:210\u201321.","journal-title":"Cancer Lett"},{"issue":"4","key":"922_CR28","first-page":"215","volume":"19","author":"H Salmon","year":"2019","unstructured":"Salmon H, Remark R, Gnjatic S, Merad M. Host tissue determinants of tumour immunity. Nat Rev Cancer. 2019;19(4):215\u201327.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"922_CR29","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642\u201362.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"922_CR30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/cgt.2010.79","volume":"18","author":"O Hemminki","year":"2011","unstructured":"Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, et al. Oncolytic adenovirus based on serotype 3. Cancer Gene Ther. 2011;18(4):288\u201396.","journal-title":"Cancer Gene Ther"},{"issue":"11","key":"922_CR31","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1038\/mt.2012.137","volume":"20","author":"V Cerullo","year":"2012","unstructured":"Cerullo V, Diaconu I, Romano V, Hirvinen M, Ugolini M, Escutenaire S, et al. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther. 2012;20(11):2076\u201386.","journal-title":"Mol Ther"},{"issue":"5304","key":"922_CR32","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"JM Bergelson","year":"1997","unstructured":"Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275(5304):1320\u20133.","journal-title":"Science."},{"issue":"1-2","key":"922_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.virusres.2006.07.009","volume":"122","author":"JJ Short","year":"2006","unstructured":"Short JJ, Vasu C, Holterman MJ, Curiel DT, Pereboev A. Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res. 2006;122(1-2):144\u201353.","journal-title":"Virus Res"},{"issue":"9","key":"922_CR34","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1128\/JVI.78.9.4454-4462.2004","volume":"78","author":"D Sirena","year":"2004","unstructured":"Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, Beerli RR, et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol. 2004;78(9):4454\u201362.","journal-title":"J Virol"},{"issue":"1","key":"922_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nm.2270","volume":"17","author":"H Wang","year":"2011","unstructured":"Wang H, Li ZY, Liu Y, Persson J, Beyer I, Moller T, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2011;17(1):96\u2013104.","journal-title":"Nat Med"},{"issue":"2","key":"922_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","volume":"73","author":"TJ Wickham","year":"1993","unstructured":"Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73(2):309\u201319.","journal-title":"Cell."},{"key":"922_CR37","unstructured":"Hemminki O. Cancer Immunotherapy with a Serotype 3 Oncolytic Adenovirus: LAP LAMBERT Academic Publishing; 2016."},{"issue":"26","key":"922_CR38","doi-asserted-by":"publisher","first-page":"15191","DOI":"10.1073\/pnas.261452898","volume":"98","author":"CJ Cohen","year":"2001","unstructured":"Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci U S A. 2001;98(26):15191\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 11","key":"922_CR39","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1099\/vir.0.83142-0","volume":"88","author":"C Fleischli","year":"2007","unstructured":"Fleischli C, Sirena D, Lesage G, Havenga MJ, Cattaneo R, Greber UF, et al. Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor. J Gen Virol. 2007;88(Pt 11):2925\u201334.","journal-title":"J Gen Virol"},{"issue":"13","key":"922_CR40","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.1128\/JVI.00514-11","volume":"85","author":"H Wang","year":"2011","unstructured":"Wang H, Li Z, Yumul R, Lara S, Hemminki A, Fender P, et al. Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. J Virol. 2011;85(13):6390\u2013402.","journal-title":"J Virol"},{"issue":"10","key":"922_CR41","doi-asserted-by":"publisher","first-page":"e1003718","DOI":"10.1371\/journal.ppat.1003718","volume":"9","author":"ZZ Lu","year":"2013","unstructured":"Lu ZZ, Wang H, Zhang Y, Cao H, Li Z, Fender P, et al. Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells. PLoS Pathog. 2013;9(10):e1003718.","journal-title":"PLoS Pathog"},{"issue":"8","key":"922_CR42","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.tips.2012.04.005","volume":"33","author":"N Arnberg","year":"2012","unstructured":"Arnberg N. Adenovirus receptors: implications for targeting of viral vectors. Trends Pharmacol Sci. 2012;33(8):442\u20138.","journal-title":"Trends Pharmacol Sci"},{"issue":"19","key":"922_CR43","doi-asserted-by":"publisher","first-page":"12125","DOI":"10.1128\/JVI.79.19.12125-12131.2005","volume":"79","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Bergelson JM. Adenovirus receptors. J Virol. 2005;79(19):12125\u201331.","journal-title":"J Virol"},{"issue":"9","key":"922_CR44","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1093\/emboj\/16.9.2294","volume":"16","author":"SS Hong","year":"1997","unstructured":"Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J. 1997;16(9):2294\u2013306.","journal-title":"EMBO J"},{"issue":"2","key":"922_CR45","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1161\/01.ATV.21.2.238","volume":"21","author":"Y Chu","year":"2001","unstructured":"Chu Y, Heistad D, Cybulsky MI, Davidson BL. Vascular cell adhesion molecule-1 augments adenovirus-mediated gene transfer. Arterioscler Thromb Vasc Biol. 2001;21(2):238\u201342.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"922_CR46","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1089\/104303403765255165","volume":"14","author":"TA Smith","year":"2003","unstructured":"Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, Mulgrew K, et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther. 2003;14(8):777\u201387.","journal-title":"Hum Gene Ther"},{"issue":"8","key":"922_CR47","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1128\/JVI.77.8.4858-4866.2003","volume":"77","author":"L Balakireva","year":"2003","unstructured":"Balakireva L, Schoehn G, Thouvenin E, Chroboczek J. Binding of adenovirus capsid to dipalmitoyl phosphatidylcholine provides a novel pathway for virus entry. J Virol. 2003;77(8):4858\u201366.","journal-title":"J Virol"},{"issue":"12","key":"922_CR48","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1002\/ijc.28615","volume":"134","author":"O Hemminki","year":"2014","unstructured":"Hemminki O, Immonen R, Narvainen J, Kipar A, Paasonen J, Jokivarsi KT, et al. In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. Int J Cancer. 2014;134(12):2878\u201390.","journal-title":"Int J Cancer"},{"issue":"4","key":"922_CR49","doi-asserted-by":"publisher","first-page":"e60032","DOI":"10.1371\/journal.pone.0060032","volume":"8","author":"A Koski","year":"2013","unstructured":"Koski A, Karli E, Kipar A, Escutenaire S, Kanerva A, Hemminki A. Mutation of the fiber shaft heparan sulphate binding site of a 5\/3 chimeric adenovirus reduces liver tropism. PLoS One. 2013;8(4):e60032.","journal-title":"PLoS One"},{"issue":"10","key":"922_CR50","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/mt.2011.144","volume":"19","author":"I Liikanen","year":"2011","unstructured":"Liikanen I, Monsurro V, Ahtiainen L, Raki M, Hakkarainen T, Diaconu I, et al. Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol Ther. 2011;19(10):1858\u201366.","journal-title":"Mol Ther"},{"issue":"3","key":"922_CR51","doi-asserted-by":"publisher","first-page":"e989771","DOI":"10.4161\/2162402X.2014.989771","volume":"4","author":"I Liikanen","year":"2015","unstructured":"Liikanen I, Koski A, Merisalo-Soikkeli M, Hemminki O, Oksanen M, Kairemo K, et al. Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncoimmunology. 2015;4(3):e989771.","journal-title":"Oncoimmunology."},{"issue":"10","key":"922_CR52","doi-asserted-by":"publisher","first-page":"e958937","DOI":"10.4161\/21624011.2014.958937","volume":"3","author":"T Ranki","year":"2014","unstructured":"Ranki T, Joensuu T, Jager E, Karbach J, Wahle C, Kairemo K, et al. Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization. Oncoimmunology. 2014;3(10):e958937.","journal-title":"Oncoimmunology."},{"issue":"4","key":"922_CR53","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8(4):247\u201358.","journal-title":"Nat Rev Immunol"},{"key":"922_CR54","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.omto.2020.02.001","volume":"16","author":"EYL Leung","year":"2020","unstructured":"Leung EYL, Ennis DP, Kennedy PR, Hansell C, Dowson S, Farquharson M, et al. NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer. Mol Ther Oncolytics. 2020;16:289\u2013301.","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"922_CR55","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0531-5565(02)00011-6","volume":"37","author":"I Massari","year":"2002","unstructured":"Massari I, Donnini A, Argentati K, Straino S, Mangoni A, Gaetano C, et al. Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats. Exp Gerontol. 2002;37(6):823\u201331.","journal-title":"Exp Gerontol"},{"issue":"9","key":"922_CR56","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd.2016.178","volume":"15","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2016;15(9):660.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"922_CR57","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1158\/1541-7786.MCR-18-0504","volume":"17","author":"N de Queiroz","year":"2019","unstructured":"de Queiroz N, Xia T, Konno H, Barber GN. Ovarian cancer cells commonly exhibit defective STING signaling which affects sensitivity to viral oncolysis. Mol Cancer Res. 2019;17(4):974\u201386.","journal-title":"Mol Cancer Res"},{"key":"922_CR58","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2017.00202","volume":"7","author":"SR Jhawar","year":"2017","unstructured":"Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, et al. Oncolytic viruses-natural and genetically engineered cancer immunotherapies. Front Oncol. 2017;7:202.","journal-title":"Front Oncol"},{"issue":"10","key":"922_CR59","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1089\/hum.2009.038","volume":"20","author":"N Bayo-Puxan","year":"2009","unstructured":"Bayo-Puxan N, Gimenez-Alejandre M, Lavilla-Alonso S, Gros A, Cascallo M, Hemminki A, et al. Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum Gene Ther. 2009;20(10):1214\u201321.","journal-title":"Hum Gene Ther"},{"issue":"6","key":"922_CR60","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1006\/mthe.2002.0599","volume":"5","author":"A Kanerva","year":"2002","unstructured":"Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther. 2002;5(6):695\u2013704.","journal-title":"Mol Ther"},{"issue":"14","key":"922_CR61","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, et al. Phase I Study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419\u201327.","journal-title":"J Clin Oncol"},{"issue":"1","key":"922_CR62","first-page":"275","volume":"8","author":"A Kanerva","year":"2002","unstructured":"Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res. 2002;8(1):275\u201380.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"922_CR63","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/mt.2015.125","volume":"23","author":"A Koski","year":"2015","unstructured":"Koski A, Bramante S, Kipar A, Oksanen M, Juhila J, Vassilev L, et al. Biodistribution analysis of oncolytic adenoviruses in patient autopsy samples reveals vascular transduction of noninjected tumors and tissues. Mol Ther. 2015;23(10):1641\u201352.","journal-title":"Mol Ther"},{"issue":"9","key":"922_CR64","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/mt.2012.115","volume":"20","author":"O Hemminki","year":"2012","unstructured":"Hemminki O, Diaconu I, Cerullo V, Pesonen SK, Kanerva A, Joensuu T, et al. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther. 2012;20(9):1821\u201330.","journal-title":"Mol Ther"},{"issue":"6","key":"922_CR65","doi-asserted-by":"publisher","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","volume":"3","author":"I Kuhn","year":"2008","unstructured":"Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One. 2008;3(6):e2409.","journal-title":"PLoS One"},{"issue":"10","key":"922_CR66","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","volume":"19","author":"A Kanerva","year":"2013","unstructured":"Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013;19(10):2734\u201344.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"922_CR67","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ijc.28696","volume":"135","author":"S Bramante","year":"2014","unstructured":"Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, et al. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer. 2014;135(3):720\u201330.","journal-title":"Int J Cancer"},{"issue":"8","key":"922_CR68","doi-asserted-by":"publisher","first-page":"676","DOI":"10.4161\/cbt.8.8.7913","volume":"8","author":"J Chang","year":"2009","unstructured":"Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J, et al. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther. 2009;8(8):676\u201382.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"922_CR69","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/1535-7163.MCT-07-2429","volume":"7","author":"X Wang","year":"2008","unstructured":"Wang X, Su C, Cao H, Li K, Chen J, Jiang L, et al. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol Cancer Ther. 2008;7(6):1598\u2013603.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"922_CR70","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.canlet.2012.01.009","volume":"319","author":"C Xu","year":"2012","unstructured":"Xu C, Sun Y, Wang Y, Yan Y, Shi Z, Chen L, et al. CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. Cancer Lett. 2012;319(2):154\u201363.","journal-title":"Cancer Lett"},{"issue":"20","key":"922_CR71","first-page":"7464","volume":"61","author":"TL DeWeese","year":"2001","unstructured":"DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61(20):7464\u201372.","journal-title":"Cancer Res"},{"issue":"6","key":"922_CR72","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.18632\/oncotarget.2901","volume":"6","author":"O Hemminki","year":"2015","unstructured":"Hemminki O, Parviainen S, Juhila J, Turkki R, Linder N, Lundin J, et al. Immunological data from cancer patients treated with Ad5\/3-E2F-Delta24-GMCSF suggests utility for tumor immunotherapy. Oncotarget. 2015;6(6):4467\u201381.","journal-title":"Oncotarget."},{"issue":"2","key":"922_CR73","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymthe.2006.01.010","volume":"14","author":"GJ Bauerschmitz","year":"2006","unstructured":"Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther. 2006;14(2):164\u201374.","journal-title":"Mol Ther"},{"issue":"2","key":"922_CR74","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ymthe.2005.10.005","volume":"13","author":"KN Barton","year":"2006","unstructured":"Barton KN, Paielli D, Zhang Y, Koul S, Brown SL, Lu M, et al. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther. 2006;13(2):347\u201356.","journal-title":"Mol Ther"},{"issue":"6","key":"922_CR75","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1158\/0008-5472.CAN-05-3033","volume":"66","author":"PD Boucher","year":"2006","unstructured":"Boucher PD, Im MM, Freytag SO, Shewach DS. A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res. 2006;66(6):3230\u20137.","journal-title":"Cancer Res"},{"issue":"7","key":"922_CR76","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/mt.2016.67","volume":"24","author":"K Taipale","year":"2016","unstructured":"Taipale K, Liikanen I, Koski A, Heiskanen R, Kanerva A, Hemminki O, et al. Predictive and prognostic clinical variables in cancer patients treated with adenoviral oncolytic immunotherapy. Mol Ther. 2016;24(7):1323\u201332.","journal-title":"Mol Ther"},{"issue":"13","key":"922_CR77","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol. 2016;23(13):4169\u201377.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"922_CR78","doi-asserted-by":"publisher","first-page":"e1265717","DOI":"10.1080\/2162402X.2016.1265717","volume":"6","author":"S Zafar","year":"2017","unstructured":"Zafar S, Parviainen S, Siurala M, Hemminki O, Havunen R, Tahtinen S, et al. Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. Oncoimmunology. 2017;6(2):e1265717.","journal-title":"Oncoimmunology."},{"issue":"10","key":"922_CR79","doi-asserted-by":"publisher","first-page":"e1490856","DOI":"10.1080\/2162402X.2018.1490856","volume":"7","author":"S Zafar","year":"2018","unstructured":"Zafar S, Sorsa S, Siurala M, Hemminki O, Havunen R, Cervera-Carrascon V, et al. CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncoimmunology. 2018;7(10):e1490856.","journal-title":"Oncoimmunology."},{"issue":"4","key":"922_CR80","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/mt.2011.31","volume":"19","author":"M Rajecki","year":"2011","unstructured":"Rajecki M, Kangasmaki A, Laasonen L, Escutenaire S, Hakkarainen T, Haukka J, et al. Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5\/3-Delta24-hNIS. Mol Ther. 2011;19(4):629\u201331.","journal-title":"Mol Ther"},{"issue":"10","key":"922_CR81","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/gt.2011.176","volume":"19","author":"JD Dias","year":"2012","unstructured":"Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 2012;19(10):988\u201398.","journal-title":"Gene Ther"},{"issue":"3","key":"922_CR82","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.18632\/oncotarget.13972","volume":"8","author":"E Oh","year":"2017","unstructured":"Oh E, Choi IK, Hong J, Yun CO. Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model. Oncotarget. 2017;8(3):4730\u201346.","journal-title":"Oncotarget."},{"issue":"22","key":"922_CR83","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1158\/1078-0432.CCR-19-0405","volume":"25","author":"H Jiang","year":"2019","unstructured":"Jiang H, Shin DH, Nguyen TT, Fueyo J, Fan X, Henry V, et al. Localized treatment with oncolytic adenovirus Delta-24-RGDOX induces systemic immunity against disseminated subcutaneous and intracranial melanomas. Clin Cancer Res. 2019;25(22):6801\u201314.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"922_CR84","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/0008-5472.CAN-16-1708","volume":"77","author":"CA Fajardo","year":"2017","unstructured":"Fajardo CA, Guedan S, Rojas LA, Moreno R, Arias-Badia M, de Sostoa J, et al. Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Cancer Res. 2017;77(8):2052\u201363.","journal-title":"Cancer Res"},{"issue":"5","key":"922_CR85","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","volume":"6","author":"A Wing","year":"2018","unstructured":"Wing A, Fajardo CA, Posey AD Jr, Shaw C, Da T, Young RM, et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol Res. 2018;6(5):605\u201316.","journal-title":"Cancer Immunol Res"},{"key":"922_CR86","doi-asserted-by":"crossref","unstructured":"Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC, et al. Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors. Mol Ther. 2020.","DOI":"10.1016\/j.ymthe.2020.02.016"},{"issue":"10","key":"922_CR87","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/mt.2010.161","volume":"18","author":"A Koski","year":"2010","unstructured":"Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, et al. Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010;18(10):1874\u201384.","journal-title":"Mol Ther"},{"issue":"2","key":"922_CR88","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/mt.2014.218","volume":"23","author":"A Kanerva","year":"2015","unstructured":"Kanerva A, Koski A, Liikanen I, Oksanen M, Joensuu T, Hemminki O, et al. Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors. Mol Ther. 2015;23(2):321\u20139.","journal-title":"Mol Ther"},{"issue":"1","key":"922_CR89","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","volume":"7","author":"JP Machiels","year":"2019","unstructured":"Machiels JP, Salazar R, Rottey S, Duran I, Dirix L, Geboes K, et al. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). J Immunother Cancer. 2019;7(1):20.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"922_CR90","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","volume":"19","author":"LN Kent","year":"2019","unstructured":"Kent LN, Leone G. The broken cycle: E2F dysfunction in cancer. Nat Rev Cancer. 2019;19(6):326\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"922_CR91","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1158\/2159-8290.CD-16-0062","volume":"6","author":"JW Shay","year":"2016","unstructured":"Shay JW. Role of telomeres and telomerase in aging and cancer. Cancer Discov. 2016;6(6):584\u201393.","journal-title":"Cancer Discov"},{"issue":"11","key":"922_CR92","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","volume":"70","author":"V Cerullo","year":"2010","unstructured":"Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010;70(11):4297\u2013309.","journal-title":"Cancer Res"},{"issue":"10","key":"922_CR93","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00262-007-0315-2","volume":"56","author":"AD Simmons","year":"2007","unstructured":"Simmons AD, Li B, Gonzalez-Edick M, Lin C, Moskalenko M, Du T, et al. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother. 2007;56(10):1653\u201365.","journal-title":"Cancer Immunol Immunother"},{"key":"922_CR94","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","volume":"4","author":"T Ranki","year":"2016","unstructured":"Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016;4:17.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"922_CR95","doi-asserted-by":"publisher","first-page":"e0131242","DOI":"10.1371\/journal.pone.0131242","volume":"10","author":"S Tahtinen","year":"2015","unstructured":"Tahtinen S, Kaikkonen S, Merisalo-Soikkeli M, Gronberg-Vaha-Koskela S, Kanerva A, Parviainen S, et al. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS One. 2015;10(6):e0131242.","journal-title":"PLoS One"},{"issue":"19","key":"922_CR96","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","volume":"23","author":"E Eriksson","year":"2017","unstructured":"Eriksson E, Milenova I, Wenthe J, Stahle M, Leja-Jarblad J, Ullenhag G, et al. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin Cancer Res. 2017;23(19):5846\u201357.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"922_CR97","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","volume":"7","author":"RK Jain","year":"2010","unstructured":"Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653\u201364.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"922_CR98","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/sj.gt.3302459","volume":"12","author":"T Pipiya","year":"2005","unstructured":"Pipiya T, Sauthoff H, Huang YQ, Chang B, Cheng J, Heitner S, et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther. 2005;12(11):911\u20137.","journal-title":"Gene Ther"},{"issue":"12","key":"922_CR99","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/gt.2010.100","volume":"17","author":"T Cherry","year":"2010","unstructured":"Cherry T, Longo SL, Tovar-Spinoza Z, Post DE. Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy. Gene Ther. 2010;17(12):1430\u201341.","journal-title":"Gene Ther"},{"issue":"6","key":"922_CR100","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/1078-0432.CCR-14-2213","volume":"21","author":"A Rodriguez-Garcia","year":"2015","unstructured":"Rodriguez-Garcia A, Gimenez-Alejandre M, Rojas JJ, Moreno R, Bazan-Peregrino M, Cascallo M, et al. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clin Cancer Res. 2015;21(6):1406\u201318.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"922_CR101","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-019-11137-5","volume":"10","author":"J Niemann","year":"2019","unstructured":"Niemann J, Woller N, Brooks J, Fleischmann-Mundt B, Martin NT, Kloos A, et al. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy. Nat Commun. 2019;10(1):3236.","journal-title":"Nat Commun"},{"issue":"1","key":"922_CR102","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.1038\/s41467-019-13744-8","volume":"10","author":"M Fusciello","year":"2019","unstructured":"Fusciello M, Fontana F, Tahtinen S, Capasso C, Feola S, Martins B, et al. Artificially cloaked viral nanovaccine for cancer immunotherapy. Nat Commun. 2019;10(1):5747.","journal-title":"Nat Commun"},{"issue":"8","key":"922_CR103","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1002\/ijc.26216","volume":"130","author":"S Pesonen","year":"2012","unstructured":"Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer. 2012;130(8):1937\u201347.","journal-title":"Int J Cancer"},{"issue":"11","key":"922_CR104","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","volume":"16","author":"P Nokisalmi","year":"2010","unstructured":"Nokisalmi P, Pesonen S, Escutenaire S, Sarkioja M, Raki M, Cerullo V, et al. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res. 2010;16(11):3035\u201343.","journal-title":"Clin Cancer Res"},{"key":"922_CR105","unstructured":"Ranki T. Preclinical and clinical evaluation of oncolytic immunotherapy with Ad5\/3-E2F1-\u039424-GMCSF (CGTG-602), a GM-CSF producing adenovirus targeted to tumors on four levels ASGCT 2012. Philadelphia; 2012."},{"issue":"1","key":"922_CR106","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/mt.2015.143","volume":"24","author":"K Taipale","year":"2016","unstructured":"Taipale K, Liikanen I, Juhila J, Turkki R, Tahtinen S, Kankainen M, et al. Chronic activation of innate immunity correlates with poor prognosis in cancer patients treated with oncolytic adenovirus. Mol Ther. 2016;24(1):175\u201383.","journal-title":"Mol Ther"},{"issue":"6","key":"922_CR107","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/mt.2013.51","volume":"21","author":"I Liikanen","year":"2013","unstructured":"Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther. 2013;21(6):1212\u201323.","journal-title":"Mol Ther"},{"issue":"1","key":"922_CR108","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/mt.2011.230","volume":"20","author":"A Koski","year":"2012","unstructured":"Koski A, Raki M, Nokisalmi P, Liikanen I, Kangasniemi L, Joensuu T, et al. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol Ther. 2012;20(1):221\u20139.","journal-title":"Mol Ther"},{"issue":"3","key":"922_CR109","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1089\/hum.2018.107","volume":"30","author":"M Garcia","year":"2019","unstructured":"Garcia M, Moreno R, Gil-Martin M, Cascallo M, de Olza MO, Cuadra C, et al. A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum Gene Ther. 2019;30(3):352\u201364.","journal-title":"Hum Gene Ther"},{"issue":"138","key":"922_CR110","doi-asserted-by":"publisher","first-page":"138ra77","DOI":"10.1126\/scitranslmed.3003578","volume":"4","author":"RA Adair","year":"2012","unstructured":"Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med. 2012;4(138):138ra77.","journal-title":"Sci Transl Med"},{"key":"922_CR111","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejphar.2018.08.042","volume":"837","author":"P Alberts","year":"2018","unstructured":"Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D. The advent of oncolytic virotherapy in oncology: the Rigvir(R) story. Eur J Pharmacol. 2018;837:117\u201326.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"922_CR112","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/1568009618666171129221503","volume":"18","author":"M Liang","year":"2018","unstructured":"Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18(2):171\u20136.","journal-title":"Curr Cancer Drug Targets"},{"key":"922_CR113","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/bs.mie.2019.05.043","volume":"635","author":"JM Santos","year":"2020","unstructured":"Santos JM, Havunen R, Hemminki A. Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition. Methods Enzymol. 2020;635:205\u201330.","journal-title":"Methods Enzymol"},{"issue":"1","key":"922_CR114","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, \u04e6hrling K, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019;7(1):145.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"922_CR115","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.cell.2018.07.035","volume":"174","author":"A Ribas","year":"2018","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2018;174(4):1031\u20132.","journal-title":"Cell."},{"issue":"17","key":"922_CR116","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658\u201367.","journal-title":"J Clin Oncol"},{"issue":"11","key":"922_CR117","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480\u201392.","journal-title":"Lancet Oncol"},{"issue":"2","key":"922_CR118","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ijc.20217","volume":"111","author":"GJ Bauerschmitz","year":"2004","unstructured":"Bauerschmitz GJ, Kanerva A, Wang M, Herrmann I, Shaw DR, Strong TV, et al. Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int J Cancer. 2004;111(2):303\u20139.","journal-title":"Int J Cancer"},{"key":"922_CR119","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fonc.2017.00093","volume":"7","author":"AL Angelova","year":"2017","unstructured":"Angelova AL, Witzens-Harig M, Galabov AS, Rommelaere J. The oncolytic virotherapy era in cancer management: prospects of applying H-1 parvovirus to treat blood and solid cancers. Front Oncol. 2017;7:93.","journal-title":"Front Oncol"},{"key":"922_CR120","doi-asserted-by":"crossref","unstructured":"Calton CM, Kelly KR, Anwer F, Carew JS, Nawrocki ST. Oncolytic viruses for multiple myeloma therapy. Cancers (Basel). 2018;10(6).","DOI":"10.3390\/cancers10060198"},{"issue":"23","key":"922_CR121","doi-asserted-by":"publisher","first-page":"5946","DOI":"10.1158\/1078-0432.CCR-14-1404","volume":"20","author":"DW Sborov","year":"2014","unstructured":"Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, et al. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res. 2014;20(23):5946\u201355.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"922_CR122","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1038\/leu.2017.120","volume":"31","author":"A Dispenzieri","year":"2017","unstructured":"Dispenzieri A, Tong C, LaPlant B, Lacy MQ, Laumann K, Dingli D, et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia. 2017;31(12):2791\u20138.","journal-title":"Leukemia."},{"issue":"6","key":"922_CR123","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109\u201319 e10.","journal-title":"Cell."},{"issue":"1","key":"922_CR124","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-018-0337-7","volume":"6","author":"L Sun","year":"2018","unstructured":"Sun L, Funchain P, Song JM, Rayman P, Tannenbaum C, Ko J, et al. Talimogene laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. J Immunother Cancer. 2018;6(1):36.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"922_CR125","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41416-019-0530-6","volume":"121","author":"J Chesney","year":"2019","unstructured":"Chesney J, Puzanov I, Collichio F, Milhem MM, Hauschild A, Chen L, et al. Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. Br J Cancer. 2019;121(5):417\u201320.","journal-title":"Br J Cancer"},{"key":"922_CR126","doi-asserted-by":"crossref","unstructured":"Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, et al. Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: a phase 2 clinical trial. JAMA Oncol. 2020.","DOI":"10.1001\/jamaoncol.2019.6152"},{"issue":"10","key":"922_CR127","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1002\/ijc.24608","volume":"125","author":"M Rajecki","year":"2009","unstructured":"Rajecki M, af Hallstrom T, Hakkarainen T, Nokisalmi P, Hautaniemi S, Nieminen AI, et al. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. Int J Cancer. 2009;125(10):2441\u20139.","journal-title":"Int J Cancer"},{"key":"922_CR128","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","volume":"4","author":"R Havunen","year":"2017","unstructured":"Havunen R, Siurala M, Sorsa S, Gronberg-Vaha-Koskela S, Behr M, Tahtinen S, et al. Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy. Mol Ther Oncolytics. 2017;4:77\u201386.","journal-title":"Mol Ther Oncolytics"},{"issue":"8","key":"922_CR129","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/mt.2016.137","volume":"24","author":"M Siurala","year":"2016","unstructured":"Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tahtinen S, et al. Adenoviral delivery of tumor necrosis factor-alpha and interleukin-2 enables successful adoptive cell therapy of immunosuppressive melanoma. Mol Ther. 2016;24(8):1435\u201343.","journal-title":"Mol Ther"},{"key":"922_CR130","doi-asserted-by":"crossref","unstructured":"Cervera-Carrascon V, Quixabeira DCA, Havunen R, Santos JM, Kutvonen E, Clubb JHA, et al. Comparison of clinically relevant oncolytic virus platforms for enhancing T-cell therapy of solid tumors. Mol Ther Oncolytics. 2020.","DOI":"10.1016\/j.omto.2020.03.003"},{"issue":"4","key":"922_CR131","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.3390\/cancers3043856","volume":"3","author":"S Lee","year":"2011","unstructured":"Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3(4):3856\u201393.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"922_CR132","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12967-018-1611-7","volume":"16","author":"SF Josephs","year":"2018","unstructured":"Josephs SF, Ichim TE, Prince SM, Kesari S, Marincola FM, Escobedo AR, et al. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. J Transl Med. 2018;16(1):242.","journal-title":"J Transl Med"},{"issue":"6","key":"922_CR133","doi-asserted-by":"publisher","first-page":"e1163462","DOI":"10.1080\/2162402X.2016.1163462","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462.","journal-title":"Oncoimmunology."},{"key":"922_CR134","doi-asserted-by":"crossref","unstructured":"Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 2018;3(7).","DOI":"10.1172\/jci.insight.99573"},{"issue":"9","key":"922_CR135","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.ymthe.2018.06.001","volume":"26","author":"JM Santos","year":"2018","unstructured":"Santos JM, Cervera-Carrascon V, Havunen R, Zafar S, Siurala M, Sorsa S, et al. Adenovirus Coding for interleukin-2 and tumor necrosis factor alpha replaces lymphodepleting chemotherapy in adoptive T cell therapy. Mol Ther. 2018;26(9):2243\u201354.","journal-title":"Mol Ther"},{"issue":"5","key":"922_CR136","doi-asserted-by":"publisher","first-page":"e1412902","DOI":"10.1080\/2162402X.2017.1412902","volume":"7","author":"V Cervera-Carrascon","year":"2018","unstructured":"Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, Tahtinen S, Karell P, et al. TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology. 2018;7(5):e1412902.","journal-title":"Oncoimmunology."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00922-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00922-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00922-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:20:15Z","timestamp":1650536415000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00922-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00922-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"2 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OH and AH are shareholders in TILT Biotherapeutics Ltd. JMS and AH are employees of TILT Biotherapeutics Ltd, and TILT-123 is a product of this company. AH and OH are also shareholders in Targovax ASA, and ONCOS-102 is a product of this company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}